Diadema Partners LP
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Diadema Partners LP reported 43 stock positions worth $125.1 million. Its top holding was Regeneron Pharmaceuticals (REGN) at 15.1% of the portfolio, followed by Eli Lilly (LLY, 12.7%) and Jazz Pharmaceuticals (JAZZ, 8.6%). Compared with Q4 2024, it opened 20 new positions, sold out of 31, added to 17 and reduced 6. The biggest buy was a new position in Regeneron Pharmaceuticals (REGN) and the biggest sale an exit from Bristol-Myers Squibb (BMY).
- Most Recent 13F
- Q2 2026
- Location
- MORRISTOWN, NJ
- CIK
- 0002026172
- Portfolio Value
- $125.1M (Q1 2025)
- SEC Filing
- 0001892688-25-000116 ↗ filed May 15, 2025
Holdings Value
Holdings 43 stocks · $125.1M
| REGN Regeneron Pharmaceuticals | 15.12% | 29,828 | $18.9M | New |
| LLY Eli Lilly & Co. | 12.74% | 19,302 | $15.9M | New |
| JAZZ Jazz Pharmaceuticals PLC | 8.65% | 87,189 | $10.8M | Add +492.4% |
| TGTX TG Therapeutics Inc. | 6.55% | 207,883 | $8.2M | Add +334.9% |
| ARGX Argenx SE - ADR | 5.74% | 12,279 | $7.2M | Add +1708.4% |
| NBIX Neurocrine Biosciences Inc. | 5.50% | 62,247 | $6.9M | New |
| SLNO Soleno Therapeutics Inc. | 5.31% | 93,002 | $6.6M | Add +29.2% |
| BMRN Biomarin Pharmaceutical Inc. | 2.99% | 52,877 | $3.7M | New |
| ALNY Alnylam Pharmaceuticals Inc. | 2.83% | 13,115 | $3.5M | New |
| PCVX Vaxcyte Inc. | 2.79% | 92,385 | $3.5M | Add +823.9% |
| IMCR Immunocore Holdings PLC-ADR | 2.30% | 96,984 | $2.9M | New |
| RYTM Rhythm Pharmaceuticals Inc. | 2.12% | 50,000 | $2.6M | Reduce -33.3% |
| SWTX Springworks Therapeutics Inc. | 2.12% | 60,000 | $2.6M | New |
| VKTX Viking Therapeutics Inc. | 2.01% | 104,121 | $2.5M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 1.89% | 164,048 | $2.4M | Add +24.4% |
| COGT Cogent Biosciences Inc. | 1.88% | 392,213 | $2.3M | Add +335.8% |
| VRDN Viridian Therapeutics Inc. | 1.75% | 162,063 | $2.2M | Add +227.6% |
| SRRK Scholar Rock Holding Corp. | 1.49% | 57,923 | $1.9M | Add +9.0% |
| ETNB 89BIO Inc. | 1.34% | 231,436 | $1.7M | New |
| NVO Novo-Nordisk A/S-Spons ADR | 1.34% | 24,618 | $1.7M | New |
| KALV Kalvista Pharmaceuticals Inc. | 1.25% | 135,509 | $1.6M | New |
| APGE Apogee Therapeutics Inc. | 1.19% | 40,000 | $1.5M | Reduce -21.0% |
| SAGE Sage Therapeutics Inc. | 1.17% | 183,466 | $1.5M | New |
| VTGN Vistagen Therapeutics Inc. | 1.13% | 565,975 | $1.4M | Add +27.9% |
| ASND Ascendis Pharma A/S | 1.04% | 8,321 | $1.3M | Reduce -67.1% |
| TRVI Trevi Therapeutics Inc. | 0.90% | 180,000 | $1.1M | New |
| RLAY Relay Therapeutics Inc. | 0.89% | 426,346 | $1.1M | Reduce -15.7% |
| PCRX Pacira Biosciences Inc. | 0.77% | 38,926 | $967K | New |
| URGN Urogen Pharma Ltd. | 0.67% | 76,220 | $843K | Add +52.4% |
| CLYM Climb Bio Inc. | 0.65% | 669,803 | $817K | Add +78.9% |
| CYTK Cytokinetics Inc. | 0.64% | 20,000 | $804K | New |
| REPL Replimune Group Inc. | 0.58% | 74,530 | $727K | Reduce -34.6% |
| REVIVA PHARMACEUTCLS HLDGS I | 0.50% | 650,723 | $621K | New |
| ALEC Alector Inc. | 0.45% | 456,546 | $562K | Add +91.0% |
| QURE Uniqure NV | 0.31% | 36,500 | $387K | New |
| OLMA Olema Pharmaceuticals Inc. | 0.30% | 100,000 | $376K | New |
| GOSS Gossamer Bio Inc. | 0.24% | 269,589 | $297K | Add +23.7% |
| PRQR Proqr Therapeutics NV | 0.22% | 207,694 | $276K | Add +31.4% |
| ELDN Eledon Pharmaceuticals Inc. | 0.17% | 64,613 | $219K | Reduce -14.8% |
| MREO Mereo Biopharma Group PL-ADR | 0.13% | 492,215 | $169K | New |
| TERN Terns Pharmaceuticals Inc. | 0.12% | 56,098 | $155K | Add +11.4% |
| SGMT Sagimet Biosciences Inc. Class A | 0.12% | 46,019 | $150K | New |
| CADL Candel Therapeutics Inc. | 0.11% | 25,045 | $142K | Add +25.2% |
Options reported separately and not counted above: AMGN calls ($32.2M), PFE calls ($22.8M), CORT puts ($17.2M), LLY puts ($17.1M), AMGN puts ($16.2M), SLNO calls ($15.7M), SLNO puts ($15.5M), REGN puts ($12.7M), JAZZ calls ($8.8M), NVO puts ($8.7M), LLY calls ($8.3M), NVO calls ($7.5M), and 47 more.
Portfolio Sells Q4 2024 → Q1 2025
| BMY Bristol-Myers Squibb Co. | Sold out | 0.00% | −10.20 |
| ABBV Abbvie Inc. | Sold out | 0.00% | −10.01 |
| TEVA Teva Pharmaceutical-SP ADR | Sold out | 0.00% | −7.52 |
| BPMC Blueprint Medicines Corp. | Sold out | 0.00% | −6.31 |
| AZN Astrazeneca PLC-Spons ADR | Sold out | 0.00% | −4.43 |
| INSM Insmed Inc. | Sold out | 0.00% | −4.38 |
| TARS Tarsus Pharmaceuticals Inc. | Sold out | 0.00% | −3.74 |
| ASND Ascendis Pharma A/S | Reduce -67.1% | 1.04% | −2.88 |
| RCUS Arcus Biosciences Inc. | Sold out | 0.00% | −2.78 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -33.3% | 2.12% | −2.61 |
| ORIC Oric Pharmaceuticals Inc. | Sold out | 0.00% | −1.95 |
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −1.49 |
| RLAY Relay Therapeutics Inc. | Reduce -15.7% | 0.89% | −1.46 |
| APGE Apogee Therapeutics Inc. | Reduce -21.0% | 1.19% | −1.39 |
| DNLI Denali Therapeutics Inc. | Sold out | 0.00% | −1.38 |
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −1.30 |
| EOLS Evolus Inc. | Sold out | 0.00% | −1.21 |
| KROS Keros Therapeutics Inc. | Sold out | 0.00% | −1.13 |
| BNTX Biontech SE-ADR | Sold out | 0.00% | −1.13 |
| REPL Replimune Group Inc. | Reduce -34.6% | 0.58% | −0.97 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −0.87 |
| GHRS GH Research PLC | Sold out | 0.00% | −0.80 |
| GERN Geron Corp. | Sold out | 0.00% | −0.80 |
| NKTR Nektar Therapeutics | Sold out | 0.00% | −0.73 |
| ONC Beone Medicines Ltd.-ADR | Sold out | 0.00% | −0.48 |
| ERAS Erasca Inc. | Sold out | 0.00% | −0.44 |
| ZVRA Zevra Therapeutics Inc. | Sold out | 0.00% | −0.40 |
| ALXO Alx Oncology Holdings Inc. | Sold out | 0.00% | −0.37 |
| ELDN Eledon Pharmaceuticals Inc. | Reduce -14.8% | 0.17% | −0.18 |
| SABS Sab Biotherapeutics Inc. | Sold out | 0.00% | −0.13 |
| CMRX Chimerix Inc. | Sold out | 0.00% | −0.11 |
| QTTB Q32 Bio Inc. | Sold out | 0.00% | −0.08 |
| EWTX Edgewise Therapeutics Inc. | Sold out | 0.00% | −0.04 |
| MIND MEDICINE MINDMED INC | Sold out | 0.00% | −0.04 |
| LVTX Lava Therapeutics NV | Sold out | 0.00% | −0.02 |
| APVO Aptevo Therapeutics Inc. | Sold out | 0.00% | −0.02 |
| LRMR Larimar Therapeutics Inc. | Sold out | 0.00% | −0.02 |
Portfolio Buys Q4 2024 → Q1 2025
| REGN Regeneron Pharmaceuticals | New | 15.12% | +15.12 |
| LLY Eli Lilly & Co. | New | 12.74% | +12.74 |
| JAZZ Jazz Pharmaceuticals PLC | Add +492.4% | 8.65% | +6.61 |
| NBIX Neurocrine Biosciences Inc. | New | 5.50% | +5.50 |
| ARGX Argenx SE - ADR | Add +1708.4% | 5.74% | +5.26 |
| TGTX TG Therapeutics Inc. | Add +334.9% | 6.55% | +4.93 |
| BMRN Biomarin Pharmaceutical Inc. | New | 2.99% | +2.99 |
| ALNY Alnylam Pharmaceuticals Inc. | New | 2.83% | +2.83 |
| IMCR Immunocore Holdings PLC-ADR | New | 2.30% | +2.30 |
| SWTX Springworks Therapeutics Inc. | New | 2.12% | +2.12 |
| VKTX Viking Therapeutics Inc. | New | 2.01% | +2.01 |
| PCVX Vaxcyte Inc. | Add +823.9% | 2.79% | +1.86 |
| SLNO Soleno Therapeutics Inc. | Add +29.2% | 5.31% | +1.66 |
| ETNB 89BIO Inc. | New | 1.34% | +1.34 |
| NVO Novo-Nordisk A/S-Spons ADR | New | 1.34% | +1.34 |
| KALV Kalvista Pharmaceuticals Inc. | New | 1.25% | +1.25 |
| SAGE Sage Therapeutics Inc. | New | 1.17% | +1.17 |
| COGT Cogent Biosciences Inc. | Add +335.8% | 1.88% | +1.09 |
| TRVI Trevi Therapeutics Inc. | New | 0.90% | +0.90 |
| PCRX Pacira Biosciences Inc. | New | 0.77% | +0.77 |
| VRDN Viridian Therapeutics Inc. | Add +227.6% | 1.75% | +0.68 |
| CYTK Cytokinetics Inc. | New | 0.64% | +0.64 |
| REVIVA PHARMACEUTCLS HLDGS I | New | 0.50% | +0.50 |
| QURE Uniqure NV | New | 0.31% | +0.31 |
| OLMA Olema Pharmaceuticals Inc. | New | 0.30% | +0.30 |
| MREO Mereo Biopharma Group PL-ADR | New | 0.13% | +0.13 |
| SGMT Sagimet Biosciences Inc. Class A | New | 0.12% | +0.12 |
| URGN Urogen Pharma Ltd. | Add +52.4% | 0.67% | +0.07 |
| GOSS Gossamer Bio Inc. | Add +23.7% | 0.24% | +0.01 |
| ALEC Alector Inc. | Add +91.0% | 0.45% | −0.06 |
| CADL Candel Therapeutics Inc. | Add +25.2% | 0.11% | −0.08 |
| CLYM Climb Bio Inc. | Add +78.9% | 0.65% | −0.11 |
| TERN Terns Pharmaceuticals Inc. | Add +11.4% | 0.12% | −0.19 |
| PRQR Proqr Therapeutics NV | Add +31.4% | 0.22% | −0.25 |
| VTGN Vistagen Therapeutics Inc. | Add +27.9% | 1.13% | −0.34 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +24.4% | 1.89% | −0.60 |
| SRRK Scholar Rock Holding Corp. | Add +9.0% | 1.49% | −1.10 |
Options Activity Q4 2024 → Q1 2025
| AMGN Amgen Inc. | call | New | 103,300 | $32.2M |
| VRTX Vertex Pharmaceuticals Inc. | call | Sold out | 57,400 | $23.1Mbefore exit |
| PFE Pfizer Inc. | call | New | 900,000 | $22.8M |
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 200,000 | $18.0Mbefore exit |
| CORT Corcept Therapeutics Inc. | put | New | 150,200 | $17.2M |
| LLY Eli Lilly & Co. | put | New | 20,700 | $17.1M |
| AMGN Amgen Inc. | put | New | 52,100 | $16.2M |
| SLNO Soleno Therapeutics Inc. | call | Add +131.9% | 219,400 | $15.7M |
| SLNO Soleno Therapeutics Inc. | put | Add +23.7% | 217,000 | $15.5M |
| REGN Regeneron Pharmaceuticals | put | New | 20,000 | $12.7M |
| ABBV Abbvie Inc. | put | Sold out | 50,000 | $8.9Mbefore exit |
| JAZZ Jazz Pharmaceuticals PLC | call | New | 70,800 | $8.8M |
| NVO Novo-Nordisk A/S-Spons ADR | put | New | 124,600 | $8.7M |
| LLY Eli Lilly & Co. | call | New | 10,000 | $8.3M |
| ACLX Arcellx Inc. | put | Sold out | 100,000 | $7.7Mbefore exit |
| NVO Novo-Nordisk A/S-Spons ADR | call | New | 108,700 | $7.5M |
| TGTX TG Therapeutics Inc. | put | Sold out | 200,000 | $6.0Mbefore exit |
| ALNY Alnylam Pharmaceuticals Inc. | put | New | 20,000 | $5.4M |
| HALO Halozyme Therapeutics Inc. | call | Sold out | 100,000 | $4.8Mbefore exit |
| APGE Apogee Therapeutics Inc. | call | New | 126,300 | $4.7M |
| CORT Corcept Therapeutics Inc. | call | New | 40,000 | $4.6M |
| BBIO Bridgebio Pharma Inc. | call | Add +31.4% | 131,400 | $4.5M |
| RARE Ultragenyx Pharmaceutical Inc. | put | Add +16.9% | 123,300 | $4.5M |
| RARE Ultragenyx Pharmaceutical Inc. | call | Add +123.7% | 117,000 | $4.2M |
| CRSP Crispr Therapeutics AG | call | Reduce -41.3% | 112,000 | $3.8M |
| BHVN Biohaven Ltd. | call | Sold out | 100,000 | $3.7Mbefore exit |
| RXRX Recursion Pharmaceuticals-A | call | Add +132.8% | 698,400 | $3.7M |
| ITCI Intra-Cellular Therapies Inc. | call | Sold out | 43,700 | $3.6Mbefore exit |
| AGIO Agios Pharmaceuticals Inc. | call | Add +17.4% | 119,700 | $3.5M |
| INSM Insmed Inc. | call | Sold out | 50,000 | $3.5Mbefore exit |
| APLS Apellis Pharmaceuticals Inc. | call | Sold out | 100,000 | $3.2Mbefore exit |
| MRNA Moderna Inc. | put | New | 100,000 | $2.8M |
| MNKD Mannkind Corp. | call | New | 519,900 | $2.6M |
| CLDX Celldex Therapeutics Inc. | call | Sold out | 100,000 | $2.5Mbefore exit |
| ANAB Anaptysbio Inc. | put | Add +17.3% | 117,300 | $2.2M |
| EWTX Edgewise Therapeutics Inc. | call | New | 98,200 | $2.2M |
| ZYME Zymeworks Inc. | call | New | 179,300 | $2.1M |
| ALT Altimmune Inc. | call | Add +109.4% | 418,800 | $2.1M |
| PCVX Vaxcyte Inc. | put | New | 51,600 | $1.9M |
| SRRK Scholar Rock Holding Corp. | call | Sold out | 43,000 | $1.9Mbefore exit |
| ANAB Anaptysbio Inc. | call | Reduce -55.0% | 96,800 | $1.8M |
| QURE Uniqure NV | call | Add +54.1% | 154,100 | $1.6M |
| KROS Keros Therapeutics Inc. | call | Add +13.2% | 147,100 | $1.5M |
| MRNA Moderna Inc. | call | New | 52,100 | $1.5M |
| VKTX Viking Therapeutics Inc. | call | New | 50,000 | $1.2M |
| COGT Cogent Biosciences Inc. | put | New | 201,400 | $1.2M |
| KALV Kalvista Pharmaceuticals Inc. | call | New | 103,300 | $1.2M |
| MREO Mereo Biopharma Group PL-ADR | call | New | 515,200 | $1.2M |
| FOLD Amicus Therapeutics Inc. | call | Add +31.4% | 131,400 | $1.1M |
| OCUL Ocular Therapeutix Inc. | call | Add +31.4% | 136,700 | $1.0M |
Showing the first 50 of 88.
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 77 | $264.6M | UTHR, RVMD, ABVX, COGT, BMRN |
| Q1 2026 | 86 | $242.2M | BRIDGEBIO PHARMA INC (BBIO 1.75 03/01/31), VKTX, UTHR, JNJ, COGT |
| Q4 2025 | 73 | $167.9M | TERN, JNJ, VKTX, ABVX, BMRN |
| Q3 2025 | 59 | $143.6M | REGN, SLNO, BMRN, PCVX, INDV |
| Q2 2025 | 46 | $160.8M | SLNO, AMGN, TGTX, NBIX, LLY |
| Q1 2025 | 43 | $125.1M | REGN, LLY, JAZZ, TGTX, ARGX |
| Q4 2024 | 54 | $88.7M | BMY, ABBV, TEVA, BPMC, RYTM |